Liraglutide
WellnessAlso known as: Victoza, Saxenda, NN2211
Well-StudiedWhat is Liraglutide?
The first once-daily injectable GLP-1 receptor agonist to achieve widespread clinical use, approved for type 2 diabetes (Victoza, 2010) and obesity (Saxenda, 2014). Historically the reference GLP-1 therapy, now largely superseded by once-weekly semaglutide in practice — but still widely prescribed with a 15+ year safety record.
How it works
A 97% homologous analog of human GLP-1 with a C16 fatty acid chain that binds albumin, extending half-life to ~13 hours and enabling once-daily dosing. Activates GLP-1 receptors in the pancreas (glucose-dependent insulin secretion, glucagon suppression), brain (appetite and satiety via hypothalamic and brainstem receptors), stomach (delayed gastric emptying), and heart (cardioprotective signaling). The LEADER cardiovascular outcome trial established significant reduction in MACE in high-risk type 2 diabetes.
What marketers claim
- ▸equivalent to semaglutide for weight loss
- ▸permanent weight loss without lifestyle changes
- ▸completely safe for everyone
- ▸cures type 2 diabetes
What evidence supports
- ✓SCALE Obesity trial (3731 participants): Saxenda 3mg achieved 8.4% mean weight loss vs 2.8% placebo at 56 weeks
- ✓LEADER trial: liraglutide reduced MACE by 13% in T2D with established CV disease (HR 0.87)
- ✓Victoza reduces HbA1c by ~1–1.5% in T2D patients
- ✓SUSTAIN-7 head-to-head: semaglutide 1mg produced 4.6% more weight loss than liraglutide 1.2mg
Research evidence
Key studies on Liraglutide, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.
SCALE Obesity and Prediabetes: liraglutide 3.0 mg for weight management
Finding: 56-week trial: 8.4% mean weight loss with liraglutide 3mg vs 2.8% with placebo; 63% of liraglutide patients achieved ≥5% weight loss vs 27% with placebo.
Limitation: All participants received lifestyle intervention (diet and exercise counseling); weight loss attributable to liraglutide alone may be somewhat lower in real-world settings.
LEADER: Liraglutide and cardiovascular outcomes in type 2 diabetes
Finding: MACE (major adverse cardiovascular events) reduced by 13% (HR 0.87, p=0.01); cardiovascular mortality reduced by 22% vs placebo over median 3.8 years.
Limitation: High-risk T2D population with established or high-risk cardiovascular disease; cardiovascular benefits may not generalize to patients using liraglutide solely for weight management.
Best for
What to expect
Realistic timeline based on available research. Individual results vary.
Week 1–4
Dose titration from 0.6mg/day upward; nausea is most prominent during this phase and typically diminishes with dose escalation.
Month 1–3
Consistent appetite suppression and early 2–4% weight loss; GI side effects diminish as the body adapts to the medication.
Month 3–6
Peak weight loss rate at therapeutic dose (3mg/day for Saxenda); SCALE trial shows approximately 8% mean weight loss at 56 weeks.
After stopping
Weight regain occurs over subsequent months — consistent with all GLP-1 class therapies, which manage but do not cure obesity.
Safety notes & concerns
Full safety guide →- ⚠GI side effects (nausea, vomiting, diarrhea) affect the majority of users early in treatment
- ⚠weight regain upon discontinuation — consistent with all GLP-1 class therapies
- ⚠FDA boxed warning: C-cell thyroid tumors in rodents; contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
- ⚠pancreatitis risk: rare but established
- ⚠requires daily injection — compliance burden vs once-weekly alternatives
- ⚠significantly less effective for weight loss than semaglutide or tirzepatide
Pairs well with
Use caution with
Frequently asked questions
Why is liraglutide being replaced by semaglutide in practice?
The SUSTAIN-7 head-to-head trial showed semaglutide 1mg once weekly produces significantly more weight loss (4.6% more) and HbA1c reduction than liraglutide 1.2mg once daily. Combined with the convenience of once-weekly vs once-daily injection, semaglutide has become the preferred GLP-1 therapy for most patients. At obesity doses (2.4mg weekly semaglutide vs 3mg daily liraglutide), the gap is even larger.
What is the difference between Victoza and Saxenda?
Both contain liraglutide as the active ingredient. Victoza is approved for type 2 diabetes management, dosed up to 1.8mg/day. Saxenda is approved for chronic weight management in adults with BMI ≥30 (or ≥27 with weight-related comorbidity), dosed up to 3mg/day. The higher dose of Saxenda drives greater appetite suppression and weight loss compared to diabetes dosing.
Related wellness peptides
skin hydration support, joint comfort, general wellness
clinically obese patients under physician supervision, type 2 diabetes management
those following longevity research who pursue protocols with medical supervision
understanding as a cautionary example of peptide marketing vs evidence
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with Liraglutide
Last updated: 2026-06-10
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.